Market Place
Sourcing Support
Acerus Update
10 Jul 2023 //
GLOBENEWSWIRE
Acerus Files For CCAA Protection
26 Jan 2023 //
GLOBENEWSWIRE
Acerus Announces Resignation of Director
26 Dec 2022 //
GLOBENEWSWIRE
Acerus Announces Amendment to Promissory Note Due to Former Serenity
03 Oct 2022 //
GLOBENEWSWIRE
Cash-depleted Acerus undergoes strategic review
21 Sep 2022 //
FIERCEBIOTECH
Acerus Announces Resignation of CFO Effective November 20, 2022
23 Aug 2022 //
GLOBENEWSWIRE
Acerus Announces Amendments to Loan Facility and Promissory Note
05 Aug 2022 //
GLOBENEWSWIRE
Acerus to Report Q2-2022 Financial Results and Host Investor Call
03 Aug 2022 //
GLOBENEWSWIRE
Acerus Announces Voting Results for the 2022 Annual Meeting
27 Jun 2022 //
GLOBENEWSWIRE
Acerus Announces Amendments to Loan Facility
24 Jun 2022 //
GLOBENEWSWIRE
Acerus Announces Amendment and Restatement of the Promissory Note
07 Jun 2022 //
GLOBENEWSWIRE
Acerus Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Acerus To Report Q1-2022 Financial Results And Host Investor Call
05 May 2022 //
GLOBENEWSWIRE
Acerus Announces Completion of Share Consolidation
26 Apr 2022 //
GLOBENEWSWIRE
Acerus Announces Share Consolidation
19 Apr 2022 //
GLOBENEWSWIRE
Acerus Announces Amendments to Loan Facility
31 Mar 2022 //
GLOBENEWSWIRE
Junshi Bio and Coherus Announce Presentation of Positive Results from CHOICE-01
15 Mar 2022 //
GLOBENEWSWIRE
Acerus To Report Q4 And FY 2021 Financial Results And Host Investor Call
10 Mar 2022 //
GLOBENEWSWIRE
Acerus Acquires Serenity Pharma and Global Rights to Noctiva
07 Mar 2022 //
GLOBENEWSWIRE
Acerus Announces Agreement to Acquire Serenity LLC and Global Rights to Noctivaâ
28 Feb 2022 //
GLOBENEWSWIRE
Acerus Announces Amendment to Loan Facilities
18 Feb 2022 //
GLOBENEWSWIRE
Acerus Pharma Announces Commercial Agreement With Verity Pharma for NATESTO
10 Jan 2022 //
GLOBENEWSWIRE
Acerus Reports Fiscal 2021 Second Quarter Financial Results
10 Aug 2021 //
GLOBENEWSWIRE
Acerus Reports Fiscal 2021 Second Quarter Financial Results
10 Aug 2021 //
GLOBENEWSWIRE
Acerus Provides Update on Litigation with Recipharm
12 Jul 2021 //
GLOBENEWSWIRE
Acerus Announces New PBM Contract
29 Jun 2021 //
GLOBENEWSWIRE
Acerus Announces Co-Promotion Agreement with Amneal for NATESTO®
10 May 2021 //
GLOBENEWSWIRE
Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma
01 Apr 2021 //
ACCESSWIRE
Acerus Announces Expansion of NATESTO® Distribution Worldwide
30 Mar 2021 //
GLOBENEWSWIRE
Acerus Announces Amendment to Credit Agreement
26 Mar 2021 //
GLOBENEWSWIRE
Acerus Announces Details of Previously Completed Rights Offering
27 Nov 2020 //
BUSINESSWIRE
Acerus Announces Waiver of Third Quarter Financial Covenant in Credit Agreement
29 Sep 2020 //
BUSINESSWIRE
Acerus Announces Launch of NATESTO® Specialty Sales Team in the United States
20 Jul 2020 //
BUSINESSWIRE
Acerus Announces Significant Improvement in NATESTO® Insurance
02 Jun 2020 //
BUSINESSWIRE
Acerus Announces Publication of Results for NATESTO®
21 Apr 2020 //
BUSINESSWIRE
Acerus Receives Notice of Deficiency From Health Canada Regarding Avanafil
20 Apr 2020 //
BUSINESSWIRE
Acerus Completes Refinancing Transactions Including US$18,000,000
21 Feb 2020 //
BUSINESSWIRE
Acerus Provides Update on NATESTO® Approval Process in Europe
10 Jan 2020 //
BUSINESS WIRE
Expanded U.S. NATETSO® Partnership Between Acerus Pharma & Aytu BioScience
02 Dec 2019 //
BUSINESS WIRE
